Sugi Predict

Sugi Predict / Compounds / SCHEMBL15399147

SCHEMBL15399147

SCHEMBL15399147

C[C@@]1(C(=O)O)CCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ CYP2C19 P33261 1/20 0.50
▸ RORC P51449 3/20 0.47
▸ ENPP2 Q13822 1/20 0.47
▸ ATXN2 Q99700 1/20 0.47
▸ ACACB O00763 1/20 0.47
▸ OPRD1 P41143 1/20 0.47
▸ OPRK1 P41145 1/20 0.47
▸ KDM1A O60341 1/20 0.47
▸ HTR2C P28335 2/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ DRD1 P21728 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15399318 1.00 MEN1 (0.53) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL632679 1.00 MEN1 (0.53) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL14636135 0.92 MEN1 (0.51) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL1468742 0.92 MEN1 (0.51) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL631455 0.92 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL26043861 0.90 SMN1; SMN2 (0.54) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL26043859 0.90 SMN1; SMN2 (0.54) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL26043854 0.90 SMN1; SMN2 (0.54) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL3919116 0.89 MEN1 (0.55) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL631190 0.88 SMN1; SMN2 (0.51) MEN1KMT2ANPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620533-A2 ANTAGONIST COMPOUNDS Adorx therapeutics Limited (GB) 2025-09-24 — — EP disclosed
US-20250243194-A1 ANTAGONIST OF ADENOSINE RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2025-07-31 — — US disclosed
EP-4188924-B1 ANTAGONIST COMPOUNDS ADORX THERAPEUTICS LTD (GB) 2025-06-18 — — EP disclosed
EP-4551296-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS Pfizer Inc. (US) 2025-05-14 — — EP disclosed
CN-119137118-A Antagonists of adenosine receptors 阿道尔克斯治疗有限公司 2024-12-13 — — CN disclosed
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS INC (US) 2024-12-05 — — US disclosed
EP-4469452-A1 ANTAGONIST OF ADENOSINE RECEPTORS Adorx therapeutics Limited (GB) 2024-12-04 — — EP disclosed
WO-2024218686-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2024-10-24 — — WO disclosed
EP-4430052-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2024-09-18 — — EP disclosed
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof NURIX THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. 2024-01-18 — — US disclosed
WO-2024009191-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2024-01-11 — — WO disclosed
US-20230293517-A1 ANTAGONIST COMPOUNDS JANSSEN PHARMCEUTICA NV (BE) 2023-09-21 — — US disclosed
WO-2023144559-A1 ANTAGONIST OF ADENOSINE RECEPTORS AdoRx Therapeutics Limited (GB) 2023-08-03 — — WO disclosed
WO-2023086399-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. (US) 2023-05-19 — — WO disclosed
CN-103492377-B As the triazolopyridine compounds of PIM kinase inhibitor ARRAY BIOPHARMA INC. (US) 2016-04-20 — — CN disclosed
EP-2678329-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-11-18 — — EP disclosed
US-8889704-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-18 — — US disclosed
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-01-02 — — US disclosed
CN-103492377-A Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC 2014-01-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 MEN1 2952/4885KMT2A 1239/4885NPSR1 1573/4885
US-20230293517-A1 ANTAGONIST COMPOUNDS ADORA2B, ADORA2A, ADORA1 MEN1 1375/4885KMT2A 2570/4885NPSR1 63/4885
US-20250243194-A1 ANTAGONIST OF ADENOSINE RECEPTORS ADORA2B, ADORA2A, ADORA1 MEN1 2232/4885KMT2A 2476/4885NPSR1 83/4885
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof TTK, HIPK1, CLK1 MEN1 3532/4885KMT2A 733/4885NPSR1 3923/4885
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 MEN1 3532/4885KMT2A 733/4885NPSR1 3923/4885
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 MEN1 3532/4885KMT2A 733/4885NPSR1 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.